Leishmaniasis, a neglected tropical disease caused by parasitic protozoa of the Leishmania genus, remains a global health concern with significant morbidity and mortality. In Thailand, the rising incidence of autochthonous leishmaniasis cases involving Leishmania (Mundinia) martiniquensis and novel Leishmania (Mundinia) orientalis underscores the critical need for accurate diagnosis and effective control strategies. This study presents a sensitive and specific nucleic acid lateral flow immunoassay (NALFIA) that integrates a duplex PCR assay with a lateral flow device (LFD) strip format. Targeting the internal transcribed spacer 1 (ITS1) region, known for its unique combination of conserved and variable sequences, this assay employs primers labeled with biotin, digoxigenin, and fluorescein isothiocyanate (FITC) markers, enabling precise species identification and differentiation of these two Leishmania species. Remarkably, the assay achieves a sensitivity that surpasses agarose gel electrophoresis, detecting as few as 10−2 parasite/μL for L. martiniquensis and 10−4 parasite/μL for L. orientalis. Notably, the assay exhibited reliable specificity, revealing no cross-amplification with other major viscerotropic Leishmania species or reference organisms. Evaluation using 62 clinical samples further confirms the effectiveness of the PCR-LFD assay, with a sensitivity of 100% for L. martiniquensis and 83.3% for L. orientalis, and an excellent agreement (κ value = 0.948) with nested PCR. This integrated assay represents a promising advancement in diagnostic tools, offering rapid and accurate results that can significantly contribute to effective disease management and control. Given the increasing relevance of these Leishmania species in current public health scenarios, this assay serves as a valuable tool for both diagnostic and research applications.
Leishmaniasis, a neglected tropical disease caused by protozoan parasites of the Leishmania genus. This disease remains a global health challenge, particularly among immunocompromised populations. In Thailand, the emergence of autochthonous infections caused by Leishmania (Mundinia) martiniquensis and Leishmania (Mundinia) orientalis underscores the urgent need for specific diagnostic markers. This study presents the first immunoproteomic characterization of these two Leishmania species, employing two-dimensional electrophoresis, Western blotting, and mass spectrometry-based proteomics to identify novel immunoreactive proteins. Pooled sera from HIV-infected patients with confirmed leishmaniasis (n = 10; five L. martiniquensis and five L. orientalis), alongside pooled control sera from Leishmania-negative HIV patients (n=30) and immunocompetent individuals (n=30), were analyzed. Using sera from Leishmania-infected HIV patients, both species exhibited species-specific and cross-species antibody recognition patterns. Notably, stronger and more diverse immunoreactivity was observed in L. martiniquensis, while L. orientalis showed fewer and less intense signals. Three shared immunoreactive proteins were identified: tubulin alpha chain from L. martiniquensis, as well as actin and enolase from L. orientalis. In silico analysis predicted actin and enolase to be highly antigenic, while all three proteins were classified as non-allergenic and contained predicted B-cell epitopes. All candidates are also known as components of extracellular vesicles, supporting their immunological relevance. These findings highlight tubulin, actin, and enolase as conserved antigens with strong potential for the development of cross-species serological tools for L. martiniquensis and L. orientalis infections. This study provides valuable insights into their antigenic profiles and supports the development of efficient diagnostic tools to address the increasing clinical cases of these emerging species.